J. Safra Sarasin Holding AG Has $524,000 Stock Holdings in Vera Therapeutics, Inc. $VERA

J. Safra Sarasin Holding AG cut its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 75.1% in the 1st quarter, HoldingsChannel reports. The fund owned 13,033 shares of the company’s stock after selling 39,294 shares during the quarter. J. Safra Sarasin Holding AG’s holdings in Vera Therapeutics were worth $524,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of VERA. GAMMA Investing LLC boosted its holdings in Vera Therapeutics by 50.5% in the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after purchasing an additional 236 shares during the period. Los Angeles Capital Management LLC acquired a new stake in shares of Vera Therapeutics in the 4th quarter valued at $46,000. Aster Capital Management DIFC Ltd acquired a new stake in Vera Therapeutics in the fourth quarter valued at about $71,000. Quantbot Technologies LP bought a new stake in shares of Vera Therapeutics during the 2nd quarter valued at approximately $51,000. Finally, Sandia Investment Management LP bought a new stake in shares of Vera Therapeutics during the fourth quarter worth $127,000. Institutional investors and hedge funds own 99.21% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on VERA shares. Guggenheim upped their price objective on Vera Therapeutics from $56.00 to $76.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Wedbush upped their target price on Vera Therapeutics from $35.00 to $43.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. TD Cowen raised their price target on shares of Vera Therapeutics from $73.00 to $78.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. HC Wainwright raised their price objective on Vera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Finally, Bank of America boosted their target price on shares of Vera Therapeutics from $65.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Eleven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Vera Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $84.58.

Vera Therapeutics Trading Down 1.5%

Shares of Vera Therapeutics stock opened at $42.50 on Thursday. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.64 and a quick ratio of 13.64. The firm has a market cap of $3.05 billion, a PE ratio of -7.67 and a beta of 0.92. Vera Therapeutics, Inc. has a 1 year low of $19.07 and a 1 year high of $56.05. The stock has a fifty day moving average price of $37.03 and a 200-day moving average price of $40.75.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same quarter in the previous year, the company earned ($0.81) EPS. Equities research analysts anticipate that Vera Therapeutics, Inc. will post -6.37 EPS for the current year.

Insider Buying and Selling

In other Vera Therapeutics news, CEO Marshall Fordyce sold 46,250 shares of the company’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the sale, the chief executive officer directly owned 151,994 shares of the company’s stock, valued at $6,429,346.20. This represents a 23.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 83,250 shares of company stock worth $3,337,770 over the last quarter. 15.90% of the stock is owned by corporate insiders.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.